Table 1.
Baseline characteristics of DOPPS participants stratified by prescription of OAC, APA, ASA or no antithrombotic agent.
| OAC | APA | ASA | None | |
|---|---|---|---|---|
|
|
||||
| Mean (SD) or % | n=2513 (6.6%) | n=4122 (10.9%) | n=8086 (21.3%) | n=23177 (61.2%) |
| Percent of patients on antithrombotic agents a | ||||
| % on OAC | 100 | 0 | 0 | 0 |
| % on APA | 7 | 100 | 0 | 0 |
| % on ASA | 16 | 26 | 100 | 0 |
|
| ||||
| Age (years) 65.3 (13.9) ** | 65.4 (12.4) ** | 65.2 (13.0) ** | 59.7 (15.5) | |
| Male (%) | 55 | 61 ** | 60 ** | 57 |
| Black | 14* | 7 ** | 11 ** | 15 |
| Time on dialysis (years) | 3.5 (4.7) ** | 4.3 (5.5)* | 3.2 (4.6) ** | 3.7 (5.4) |
| BMI | 26.4 (6.5)* | 24.1 (5.3)* | 25.5 (5.6) ** | 24.3 (5.6) |
| Catheter Use (%) | 38* | 19* | 26 ** | 25 |
| Hemoglobin (g/dL) | 11.13 (1.63) ** | 10.85 (1.73) ** | 11.07 (1.65) ** | 10.68 (1.72) |
| Albumin (g/dL) | 3.59 (0.51)* | 3.69 (0.49)* | 3.65 (0.51)* | 3.68 (0.55) |
| Calcium (mg/dL) | 9.14 (0.93)* | 9.13 (0.91)* | 9.16 (0.91) ** | 9.07 (1) |
| Phosphorous (mg/dL) | 5.31 (1.77) ** | 5.32 (1.68) ** | 5.44 (1.73) ** | 5.67 (1.87) |
| PTH | 296 (415)* | 249 (340) ** | 273 (397) ** | 306 (419) |
| Dialysis dose (spKt/V) | 1.42 (0.33) | 1.38 (0.32) | 1.40 (0.33) | 1.37 (0.33) |
| Comorbid Conditions: (%) | ||||
| CAD | 58.0 ** | 53.2 ** | 61.6 ** | 35.4 |
| CHF | 46.8 ** | 37.5 ** | 42.1 ** | 29.9 |
| Cerebrovascular disease | 24.8 ** | 27.8 ** | 22.0 ** | 11.8 |
| PVD | 34.5 ** | 39.0 ** | 32.7 ** | 18.7 |
| Atrial Fibrillation | 34.1 ** | 10.2 ** | 12.4 ** | 7.7 |
| Other cardiac disease | 40.4 ** | 33.6 ** | 33.0 ** | 24.6 |
| Hypertension | 80.4 | 79.4 ** | 84.3 ** | 78.0 |
| Cancer (excluding skin) | 14.9* | 10.2 | 12.3 | 11.2 |
| Diabetes | 42.0 ** | 46.0 ** | 47.4 ** | 33.3 |
| GI bleed | 6.7 | 6.0 | 5.6* | 6.5 |
| HIV/AID | 0.4* | 0.3* | 0.3 ** | 1.4 |
| Lung disease | 16.6 ** | 13.0 ** | 13.7 ** | 9.6 |
| Neurological disorder | 11.9 | 10.5* | 10.6 | 9.5 |
| Psychiatric disease | 23.2 | 15.4 | 19.1 | 17.8 |
| Recurrent cellulitis/gangrene | 12.7 ** | 11.0 ** | 9.0 ** | 6.1 |
| Deep vein thrombosis | 14.0 ** | 4.0 ** | 3.8 | 2.9 |
| CHADS2 Score: (%) | ||||
| CHADS2 Low (score=0) | 7.4* | 9.5 ** | 5.7 ** | 12.5 |
| CHADS2 Moderate (score=1) | 20.7 ** | 20.7 ** | 21.8 ** | 35.1 |
| CHADS2 High (score ≥ 2) | 71.9 ** | 69.8 ** | 72.6 ** | 52.4 |
| mORBI Score: (%) | ||||
| mORBI Low (score=0,1) | 56.5 ** | 51.7 ** | 56.2 ** | 68.6 |
| mORBI Moderate (score=2) | 33.3 ** | 36.2 ** | 34.7 ** | 25.7 |
| mORBI High (score=3,4) | 10.2 ** | 12.1 ** | 9.1 ** | 5.8 |
| Eventsb: | ||||
| Major Bleeding | 0.078* | 0.062 | 0.063 | 0.049 |
| Stroke | 0.033 | 0.034* | 0.025 | 0.021 |
| CV Mortality | 0.111* | 0.081* | 0.082 | 0.059 |
| All-Cause Mortality | 0.240* | 0.165* | 0.174 | 0.132 |
| Follow up time, years | 1.47 (0.98) | 1.57 (0.90) | 1.57 (0.98) | 1.59 (1.01) |
Based on data from DOPPS phase 1, 2, and 3 (1996–2008) Adjusted for phase and region; accounted for facility clustering; p-values from logistic or mixed models with no-antithrombotic agent category as reference. Type 3 overall tests were significant at p<0.01 for all variables (indicating that patients were not all the same across all four categories) except for dialysis dose (spKt/V) p=0.75, neurologic disorder p=0.15, and psychiatric disorder p=0.10.
p < 0.05
p < 0.0001 with None as the referent
OAC (warfarin [85% of total OAC], dicumarol, phenprocoumon, fluindione); APA-other than aspirin (ticlopidine [36%], clopidogrel [35%], dipyridamole [14%], pentoxifylline [14%] medication not mutually exclusive)
events during follow up; not mutually exclusive; rate per patient year;